CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 9,651 enrolled
Drug / intervention
Semaglutide +1 moredrug
Likely dose
Semaglutide 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03914326
NCT03914326Phase 3Completed
CompareCT.gov

Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes

Novo Nordisk A/S·interventional·Posted Apr 16, 2019·Updated Dec 11, 2025

In Brief

A Phase 3 clinical trial evaluating Semaglutide and Placebo (semaglutide) for Diabetes Mellitus, Type 2. Completed, enrolled 9,651 participants across 492 sites in 34 countries.

Detailed Summary

The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must take one tablet with water every morning on an empty stomach and not eat or drink anything for at least 30 minutes. The study will last for about 3.5-5 years. Participants will have up to 25 clinic visits and 1 phone call with the study doctor. Women cannot be in the study if pregnant, breast-feeding or if they plan to become pregnant during the study period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesAlgeria, Argentina, Austria, Belgium, Brazil, Canada, China, Colombia, Croatia, Czechia, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, Romania, Russia, Serbia, Slovakia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 16, 2019
Enrollment StartJun 17, 2019
Primary CompletionAug 23, 2024
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 7.2 years ago

Interventions

Semaglutidedrug

Increasing doses (3 mg/7 mg/14 mg) of semaglutide tablets to be taken with water at the same time every morning in a fasting state

Placebo (semaglutide)drug

Placebo tablets to be taken with water at the same time every morning in a fasting state